Medicine

Sustained Response to Lorlatinib and Pemetrexed in ALK Fusion–Positive Anaplastic Thyroid Carcinoma With Multiple Distant Metastases: A Case Report

Matheus Sewastjanow-Silva, M. Cabanillas, E. D. Dal Lago, M. T. Cunha, M. Zafereo, A. El-Naggar, R. Ferrarotto, Y. Elamin, L. D. de Sousa

2026.2.1JCO Precision Oncology

DOI: 10.1200/po-25-00548

Abstract

a tyrosine kinase inhibitor with activity against anaplastic lymphoma kinase (ALK) and

Citation format

SEWASTJANOW-SILVA, Matheus, et al. Sustained response to lorlatinib and pemetrexed in ALK fusion–positive anaplastic thyroid carcinoma with multiple distant metastases: A case report. JCO Precision Oncology, 2026, 10(2): e2500548.